TY - JOUR
AU - Torre, Donato
AB - 9. Adjei G. Clinical neurotoxicity of artemisinin infection in patients with clinical and/or clinical, microbiological, and histological drugs in malaria treatment. In: Program and immunological AIDS. resolution of infection [6, 7]. In contrast, abstracts of the 4th Multilateral Initiative on First, a close correlation between col- Malaria conference. 2005. it seems that, in the HAART era, diarrheal 10. Kissinger E, Hien TT, Hung NT, et al. Clinical onization with C. difficile and episodes of illness caused by enteric bacterial patho- and neurophysiological study of the effects of acute diarrhea in an immunocompromi- gens, such as Salmonella species, Shigella multiple doses of artemisinin on brain-stem sed patient is often tricky to evaluate and species, Campylobacter species, and Yersi- function in Vietnamese patients. Am J Trop Med Hyg 2000; 63:48–55. establish. It has been reported that 125% nia species other than C. difficile, continue 11. van Vugt M, Angus BJ, Price RN, et al. A case- of patients admitted to the hospital are to occur, especially among HIV-1–infected control auditory evaluation of patients treated colonized with C. difficile and that these patients with advanced disease. However, with artemisinin derivatives for multidrug- resistant Plasmodium falciparum malaria. Am patients were less likely to 
TI - Is Clostridium difficile the Leading Pathogen in Bacterial Diarrhea in HIV Type 1–Infected Patients?
JO - Clinical Infectious Diseases
DO - 10.1086/502661
DA - 2006-04-15
UR - https://www.deepdyve.com/lp/oxford-university-press/is-clostridium-difficile-the-leading-pathogen-in-bacterial-diarrhea-in-WUy7xPuGUc
SP - 1215
EP - 1216
VL - 42
IS - 8
DP - DeepDyve
ER -